<DOC>
	<DOCNO>NCT02882412</DOCNO>
	<brief_summary>Long-term use opioids chronic pain grow health social problem , mainly risk dependence . Buprenorphine/naloxone use substitution therapy opioid dependence . This substitution therapy patient opioid dependence lessens withdrawal symptom crave . There limited research effectiveness buprenorphine/naloxone patient chronic pain iatrogenic opioid dependence . The primary aim study investigate effectiveness buprenorphine/naloxone patient suffer chronic pain iatrogenic induce dependence opioids . This study investigate effect opioid substitution buprenorphine/naloxone patient suffer chronic pain use long-term opioids , pain withdrawal symptom primary outcome measure . Secondary outcome measure crave , substance use , psychiatric comorbidity quality life .</brief_summary>
	<brief_title>Effectiveness Buprenorphine/Naloxone</brief_title>
	<detailed_description>This prospective open-label observational cohort study ( exploratory pilot ) . Investigators include 20 patient 18 65 year chronic pain dependence opioids , refer physician replacement opioids buprenorphine/naloxone . Exclusion criterion contraindication buprenorphine/naloxone patient psychiatric disorder require acute treatment . The degree pain withdrawal symptom assess Quantitative Sensory Testing ( QST ) measurement follow questionnaire : Visual Analog Scale ( VAS ) , Objective Withdrawal Scale ( OWS ) Subjective Withdrawal Scale ( SWS ) . Secondary , crave substance use/degree opioid dependence study use Current Opioid Misuse Measure ( COMM ) Obsessive Compulsive Drug use Scale ( OCDS ) . Psychiatric comorbidity assess use follow questionnaire : Depression , Anxiety Stress Scale ( DASS ) , Personality Inventory DSM-5 ( PID 5-BF ) , The 20-item Toronto Alexithymia Scale ( TAS-20 ) , Inventory Depressive Symptomatology ( IDS ) , Perseverative Thinking Questionnaire ( PTQ ) Mini International Neuropsychiatric Interview ( MINI ) . These questionnaire part standard assessment department psychiatry Radboud University Medical Centre , Nijmegen . The EuroQol five dimension questionnaire ( EQ5D ) use assess quality life . During replacement opioids buprenorphine/naloxone , buprenorphine/naloxone protocol use .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>Adult men woman age 18 65 year suffer chronic pain ( pain 6 month ) iatrogenic opioid dependence ( accord DSM5 criterion ) inform consent use data scientific analysis . Contraindications buprenorphine/naloxone , severe respiratory insufficiency , severe hepatic insufficiency , alcohol intoxication delirium tremens . In addition participant psychiatric disorder require acute treatment exclude , instance acute psychosis , acute manic episode patient suicidal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>effectiveness</keyword>
	<keyword>buprenorphine/naloxone</keyword>
	<keyword>iatrogenic opioid dependence</keyword>
</DOC>